Novel pharmacological compounds for the treatment and prevention of cataracts

New family of molecules derived from Isoquercetin for the treatment and/or prevention of inflammatory and degenerative eye diseases.

Glycolipid mimetics with selective anti- or pro-inflammatory response

Novel glycolipid mimetics able to express anti-inflammatory or adjuvant activity in a context dependent manner. The compounds can be used for the…

Identification of therapeutic candidates for Congenital Central Hypoventilation Syndrome (CCHS)

An in vitro screening method by NMR spectroscopy of potential therapeutic compounds for Congenital Central Hypoventilation Syndrome (CCHS). The…

Compounds for the treatment of canine Leishmaniosis

New family of compounds with demonstrated in vitro efficacy against intracellular parasites responsible for leishmaniasis and American…

SGK1 inhibitors to treat cardiovascular and neurodegenerative diseases

Selective SGK1 kinase inhibitors, blood-brain barrier-permeable, as drug candidates for the treatment of neurodegenerative diseases (such as…

Antiviral compound against HSV-1 and HSV-2 aciclovir resistant strains

New antiviral compound against HSV-1 and HSV-2 that can be used in combination with other drugs or to treat resistant strains to conventional…

Light-controlled beta blockers for the treatment of ocular diseases

Compounds useful as reversible visible-light-regulated antagonists for the localized and temporally restricted activation of beta-adrenoceptors, with…

Styryl benzothiazolium salts as antiparasitic therapy

New compounds to treat parasitic diseases such as Chagas disease, leishmaniasis and trypanosomiasias. These derivatives act on a new target: G-…

A new antiviral familiy of compounds with selective activity against coronaviruses

New family of molecules with potent and selective antiviral activity in cellular models of infection by various coronaviruses such as SARS-CoV-2,…

New antiviral familiy of compounds targeting of non-essential viral proteins

Novel antiviral strategy targeting viral non-essential proteins (NEPs), scarcely prone to adaptive mutations. As a proof of concept, SARS-CoV-2 ORF9b…